Filing Details

Accession Number:
0000899243-16-021416
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-02 06:16:59
Reporting Period:
2016-06-01
Filing Date:
2016-06-02
Accepted Time:
2016-06-02 06:16:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358762 Reata Pharmaceuticals Inc RETA Pharmaceutical Preparations (2834) 113651945
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1662392 John Colin Meyer 2801 Gateway Drive, Suite 150
Irving TX 75063
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2016-06-01 10,172 $0.00 10,172 No 4 C Direct
Class A Common Stock Acquisiton 2016-06-01 10,000 $11.00 20,172 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Class B common stock Disposition 2016-06-01 10,172 $0.00 10,172 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
113,985 No 4 C Direct
Footnotes
  1. The Class B common stock is convertible into Class A common stock on a one-for-one basis (a) at the holder's election at any time after the date that is six months following the date of the closing of the initial public offering of the company's Class A common stock, (b) at the holder's election prior to that time subject to certain conditions, or (c) at the option of the company's board of directors, in its sole discretion, at any time or multiple times from time to time on or before the closing of the initial public offering. The conversion right of the Class B common stock has no expiration date.